Next Article in Journal
Analysis of the Intestinal and Faecal Bacterial Microbiota of the Cervidae Family Using 16S Next-Generation Sequencing: A Review
Next Article in Special Issue
Ultraviolet-C-Based Mobile Phone Sanitisation for Global Public Health and Infection Control
Previous Article in Journal
Gut Protective Effect from Newly Isolated Bacteria as Probiotics against Dextran Sulfate Sodium and Carrageenan-Induced Ulcerative Colitis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 11
Issue 7
10.3390/microorganisms11071859
Review Report
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Composite Interventions on Outcomes of Severely and Critically Ill Patients with COVID-19 in Shanghai, China

Microorganisms 2023, 11(7), 1859; https://doi.org/10.3390/microorganisms11071859
by Jiasheng Shao 1,2,†, Rong Fan 2,3,†, Chengnan Guo 4, Xuyuan Huang 5, Runsheng Guo 6, Fengdi Zhang 7, Jianrong Hu 8, Gang Huang 9,* and Liou Cao 10,*
Reviewer 1: Anonymous
Reviewer 2:
Francisco Epelde
Microorganisms 2023, 11(7), 1859; https://doi.org/10.3390/microorganisms11071859
Submission received: 25 June 2023 / Revised: 17 July 2023 / Accepted: 19 July 2023 / Published: 23 July 2023
(This article belongs to the Special Issue Advances in Public Health Microbiology 2023)

Round 1

Reviewer 1 Report

This is a very interesting paper with a lot of data

I have a few minor comments for the authors to adress

In Abstract, I am not sure Paxlovid had significnt result on survival, please check. Also check results for glucocorticoid. Dont put comma before and

Line 53, green mark - remove

Line 59 missing space (check through the manuscript)

Line 61 - specify year

Line 106 - space extra

I do not understand why would patients in antiviral not receive antivirals, please clarify in methods how you divided patients. Also I would suggest you keep to one terminology in the manuscript i.e. mechanism of action of drugs or drug name but not mix and match both

Consider increasing font and resolution of figure 1.

Table 1 is completely unclear why you have number of patients per domain (single) and then all, consider presenting this differently.

Table 2 is missing inclusion criteria related to medications...

Data was collected by face-to-face or telephone interview with the participants, their relatives, or health care professional in our hospital - I think that this method of collection may yield substantial bias and variations so please comment on this in discussion. Also repeated statistical analysis creates space for a false positive, and cesored data i.e. for deceased patients and how their HRQoL was treated should be clarified in the methods.

Resolution in Figure 2 also needs to be improved

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

The study is of interest as it is the first real-world observational trial to study a combination treatment of COVID patients that includes Paxlovid and remdesivir. 

The number of patients is large enough to be statistically significant.

As a criticism, the study was conducted in a single country, which may offer important racial differences, but nevertheless I think this is something the authors can think about for a second version.

On the other hand, the tables need to be improved as they are difficult to understand and visualise. 

Author Response

Please see the attachment

Author Response File: Author Response.docx

Back to TopTop